MedPal AI (MPAL) has acquired a pharmacy facility in Runcorn, UK, for a cash consideration of £310,000, supporting the expansion of its pharmacy operations and targeting EBITDA breakeven at 80,000 items per month.
The acquisition, completed through its wholly owned subsidiary Medpal Limited, includes assets from Remedi Solutions, which entered administration in December 2024. NHS-verified data shows the site dispensed about 1 million prescription items in 2024, equating to a historical annualised turnover of about £10 million at current NHS average item values.
The transaction involved reimbursing £280,000 of prior costs and a final £30,000 payment to administrators. A new holding company, New Performance Health Limited, has been established to manage the lease of new premises in Runcorn, with the pharmacy business set to transfer as part of an internal reorganisation.
Operationally, MedPal now runs two NHS dispensing hubs in Swaffham and Runcorn, leveraging automation, care home contracts and digital integration via its platform. The company is applying its patient reactivation strategy at scale to the newly acquired site.
Management noted that the group is currently dispensing more than 40,000 items per month, with pharmacy-level EBITDA breakeven expected at 80,000 items per month. NHS pharmacy gross margins exceed 34%, offering strong operating leverage as volumes increase.
MedPal AI’s Chief Executive Officer Jason Drummond said: “For a total spend of less than half a million pounds we have secured an NHS dispensing hub in a strategically critical location with a patient book that NHS-verified data shows historically delivered over £10 million of annualised turnover. We have already proven at Swaffham that our reactivation strategy works. We are now running that same programme, at materially greater scale, across the Remedi book. Our pharmacy operations are growing rapidly, currently dispensing 42,000 items a month and rising, with a mapped path to pharmacy-level breakeven at 80,000 items a threshold the acquired Runcorn site alone comfortably exceeded throughout 2024”
View from Vox
This acquisition adds meaningful scale to MedPal AI’s pharmacy operations at a relatively low entry cost. The historical throughput at Runcorn suggests the breakeven target is achievable, while margins and operating leverage provide upside if volumes continue to ramp. The key focus now is execution - specifically, how quickly the company can reactivate patients and convert that into sustained dispensing growth.